Department of General Surgery, The Second Affiliated Hospital, College of Medicine, Zhejiang University, 88 Jiefang Street, Hangzhou 310009, People's Republic of China.
Department of Endocrinology, The Second Affiliated Hospital, College of Medicine, Zhejiang University, 88 Jiefang Street, Hangzhou 310009, People's Republic of China.
Vascul Pharmacol. 2018 Oct;109:17-26. doi: 10.1016/j.vph.2018.05.010. Epub 2018 Jun 4.
Dipeptidyl peptidase 4 (DPP-4) inhibitor is a novel group of medicine employed in type 2 diabetes mellitus (T2DM),which improves meal stimulated insulin secretion by protecting glucagon-like peptide-1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) from enzymatic degradation. Cardiovascular diseases are serious complications and leading causes of mortality among individuals with diabetes mellitus. Glycemic control per se seems to fail in preventing the progression of diabetic cardiovascular complications. DPP-4 has the capability to inactivate not only incretins, but also a series of cytokines, chemokines, and neuropeptides involved in inflammation, immunity, and vascular function. Pre-clinical studies suggested that DPP-4 inhibitors may have potential cardiovascular protective effects in addition to their antidiabetic actions. In recent years, a number of clinical trials have been conducted to evaluate the effect of different DPP-4 inhibitors on the cardiovascular system. We herein review the available clinical studies in cardiovascular effects played by each DPP-4 inhibitor and discuss the prospective application of DPP-4 inhibitors on cardiovascular diseases.
二肽基肽酶 4（DPP-4）抑制剂是一类新型的用于 2 型糖尿病（T2DM）的药物，它通过保护胰高血糖素样肽-1（GLP-1）和葡萄糖依赖性胰岛素释放肽（GIP）免受酶解来改善餐时胰岛素分泌。心血管疾病是糖尿病患者的严重并发症和主要死亡原因。单纯控制血糖似乎不能阻止糖尿病心血管并发症的进展。DPP-4 不仅可以使肠降血糖素失活，还可以使一系列参与炎症、免疫和血管功能的细胞因子、趋化因子和神经肽失活。临床前研究表明，DPP-4 抑制剂除了具有抗糖尿病作用外，可能还有潜在的心血管保护作用。近年来，进行了多项临床试验以评估不同 DPP-4 抑制剂对心血管系统的影响。本文综述了每种 DPP-4 抑制剂在心血管作用方面的现有临床研究，并讨论了 DPP-4 抑制剂在心血管疾病中的应用前景。
